1 |
PAR 1 deficient STZ induced diabetic nephropathy model in mice |
C57BL/6 mice |
PAR1 antagonist p1pal-12 |
Mesangial proliferation and
fibronectin production was reduced upon co-administration of PAR1
antagonist p1pal-12 |
4 |
2 |
PAR1 inhibition in type-2 diabetic nephropathy model in mice |
BTBRob/ob mice |
PAR1 antagonist vorapaxar |
Vorapaxar
treatment did not correct the glomerular damage but mesangial expansion
was significantly reduced |
14 |
3 |
eNOS deficient diabetic nephropathy model in mice |
C57BL/6J mice |
anti-TF antibody AF3178 |
Administration of anti-TF antibody AF3178 has
significantly reduced TF dependent PAR2 induced kidney dysfunction by
correcting increase in urinary albumin, thickening of glomerular
basement membrane (GBM), glomerulosclerosis and fibrin deposition |
63 |
4 |
Role of FXa and PAR2 interaction in diabetic nephropathy model in
mice |
Akita mice |
FXa inhibitor edoxaban |
Inhibition of FXa by
edoxaban retarded the invasion of macrophages in glomeruli by PAR2
inactivation. It also ameliorated the diabetic nephropathy by reduction
in urinary albumin excretion, mesangial matrix production and also
reduced PAR2 mediated inflammation |
59 |
5 |
Role of PAR 2 in STZ induced diabetic nephropathy model in mice |
C57Bl/6 mice |
PAR 2 gene knockout |
PAR2 deficiency resulted in reduced
albuminuria but it was accompanied by increased mesangial expansion and
collagen deposition in the glomeruli |
64 |
6 |
Role of PARs in thrombin induced podocyte injury in NS (nephritic
syndrome) model in rat |
Wistar rat |
Thrombin inhibitor hirudin |
Administration of hirudin has attenuated the thrombin induced podocyte
injury by inhibition of ERK1/2 phosphorylation and correcting increased
proteinuria levels |
68 |
7 |
Role of PAR1 in podocyte injury in doxorubicin induced nephropathy
in mice model |
BALB/c and C57BL/6 mice |
PAR 1 antagonist Q94 |
Administration of Q94 has improved the doxorubicin induced loss of
podocin and nephrin proteins, and also corrected the increased
albuminuria, plasma creatinine, oxidative stress and glomerulosclerosis
levels |
49 |
8 |
Role of PAR 2 in renal tubular epithelial inflammation in UUO mice
model |
Male CD-1 mice |
PAR 2 antagonist FSLLRY-Amide, mTOR inhibitor
rapamycin and its activator MYH1485 |
Inhibition of PAR 2 by
FSLLRY-Amide has attenuated the UUO induced renal tubular epithelial
inflammation via activation of mTOR signaling pathway |
1 |
9 |
Role of PAR 4 in acute renal ischemia reperfusion injury induced AKI
model in mice |
C57BL/6J and PAR4KO mice |
PAR 4 gene knockout |
Post
I/R injury insult deletion of PAR4 gene facilitated the progression of
I/R induced renal injury while contrarily protecting the podocyte
damage. |
114 |
10 |
Role of PAR2 in mediating focal segmental glomerulosclerosis in
drug induced nephrotoxicity model |
Male Sprague-Dawley rats |
Adriamycin (ADR) and PAR2 inhibitor FSLLRY-NH2 (FSL) |
Administration of
adriamycin resulted in nephropathy with increased cytokine levels and
also podocyte damage which was corrected by PAR2 inhibitor FSLLRY-NH2
(FSL) |
87 |
11 |
Role of PAR2 blockade in mediating renal injury in a
lipopolysaccharide (LPS) induced endotoxemic rat model |
Male wistar rat |
Lipopolysaccharide (LPS) and PAR2 blocking peptide sc-9278 P |
Blockade of PAR2 by peptide sc-9278 P has attenuated the LPS induced
elevated TNF-α, ET-1 levels and also iNOS protein expression |
109 |
12 |
Beneficial effect of PAR2 in VEGF inhibitor induced glomerular and
podocyte injury in mice model |
C57BL/6J |
B20–4.1.1(a mouse anti-VEGF
Ab), PAR2 agonist( 2f-LIGRLO) PAR2 knockout and eNOS knockout |
PAR2 has
attenuated the damage of renal tissue induced by the VEGF inhibitor |
81 |
13 |
Protective effects of dual blockade of PAR1 AND PAR2 in DKD |
eNOS
deficient Akita diabetic mice |
PAR1 agonist (TFLLR-NH2) and PAR2
agonist (2f-LIGRLO) |
DUAL blockade by PAR1 and PAR-2 attenuates DKD by
distinct mechanisms |
65 |